PolyActiva
Uses a unique drug-polymer conjugate technology to enable site specific drug delivery from medical device components, such as implants, films, or fibers.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | AUD40.0m | Series C | |
| Total Funding | 000k | ||
Related Content
PolyActiva is a biotechnology company specializing in the development of therapeutic products for ocular diseases. The company focuses on creating innovative ocular implants that provide sustained drug release, targeting conditions such as glaucoma and endophthalmitis. PolyActiva operates in the pharmaceutical and healthcare markets, primarily serving patients and healthcare providers who require advanced treatments for eye diseases. The business model revolves around research and development, clinical trials, and eventual commercialization of its proprietary drug delivery systems. Revenue is generated through product sales, licensing agreements, and potential partnerships with larger pharmaceutical companies. PolyActiva's products are designed to offer high dose loadings and complete bioerosion, ensuring effective and safe treatment over extended periods. The company is headquartered in Melbourne, Australia, and collaborates with institutions like the Monash Institute of Pharmaceutical Sciences for its research activities.
Keywords: ocular implants, sustained drug release, glaucoma treatment, endophthalmitis prevention, biodegradable implants, pharmaceutical innovation, healthcare, biotechnology, drug delivery systems, clinical trials.